Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.70 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.70 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30608768 | 0.91 | LMNA (0.74) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6060610 | 0.90 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL236108 | 0.90 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL11852751 | 0.89 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL24680959 | 0.88 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL441997 | 0.88 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13678671 | 0.88 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15197971 | 0.88 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5491562 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4946508 | 0.87 | LMNA (0.75) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097706-B2 | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein | Hammi Holdings Co., Ltd (KR) | 2012-01-17 | — | — | US | claimed |
| US-20100249395-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-09-30 | — | — | US | claimed |
| EP-2220090-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2010-08-25 | — | — | EP | claimed |
| WO-2009066892-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2009-05-28 | — | — | WO | claimed |
| US-20240158833-A1 | Compositions and Methods for Labeling Modified Nucleotides in Nucleic Acids | NEW ENGLAND BIOLABS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4294936-A1 | COMPOSITIONS AND METHODS FOR LABELING MODIFIED NUCLEOTIDES IN NUCLEIC ACIDS | New England Biolabs, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022178093-A1 | COMPOSITIONS AND METHODS FOR LABELING MODIFIED NUCLEOTIDES IN NUCLEIC ACIDS | NEW ENGLAND BIOLABS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-8097706-B2 | Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used therein | Hammi Holdings Co., Ltd (KR) | 2012-01-17 | — | — | US | disclosed |
| US-20100249395-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
| EP-2220090-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009066892-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2009-05-28 | — | — | WO | disclosed |
| EP-1140967-A1 | TARGETED GENE TRANSFER USING G PROTEIN COUPLED RECEPTORS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039145-A1 | TARGETED GENE TRANSFER USING G PROTEIN COUPLED RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249395-A1 | METHODS FOR PREPARING CAPECITABINE AND BETA-ANOMER-RICH TRIALKYL CARBONATE COMPOUND USED THEREIN | TYMP, SI, DPYD | LMNA 3050/4885THRB 4265/4885MTOR 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.